Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
38,466,645
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
5,656,228
-
Shares change
-
-268,005
-
Total reported value, excl. options
-
$16,718,296
-
Value change
-
-$789,370
-
Number of buys
-
4
-
Number of sells
-
-14
-
Price
-
$2.96
Significant Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q3 2022
30 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock as of Q3 2022.
Protara Therapeutics, Inc. - Common Stock (TARA) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,656,228 shares
of 38,466,645 outstanding shares and own 15% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2,708,067 shares), ORBIMED ADVISORS LLC (830,641 shares), VANGUARD GROUP INC (427,388 shares), PERCEPTIVE ADVISORS LLC (290,051 shares), BOXER CAPITAL, LLC (209,227 shares), BAKER BROS. ADVISORS LP (199,671 shares), Ikarian Capital, LLC (188,664 shares), CITADEL ADVISORS LLC (170,522 shares), GEODE CAPITAL MANAGEMENT, LLC (83,644 shares), and RENAISSANCE TECHNOLOGIES LLC (79,200 shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.